Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade)

Stock Information for Voyager Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Voyager Therapeutics Inc.

Voyager Reports Third Quarter 2025 Financial and Operating Results
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
Voyager to Present at Upcoming Investor Conferences
Voyager Reports Second Quarter 2025 Financial and Operating Results
Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication
Voyager Reports First Quarter 2025 Financial and Operating Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.